Titre : Groupes témoins

Groupes témoins : Questions médicales fréquentes

Termes MeSH sélectionnés :

Attention Deficit Disorder with Hyperactivity
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Groupes témoins : Questions médicales les plus fréquentes", "headline": "Groupes témoins : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Groupes témoins : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-25", "dateModified": "2025-04-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Groupes témoins" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Méthodes", "url": "https://questionsmedicales.fr/mesh/D008722", "about": { "@type": "MedicalCondition", "name": "Méthodes", "code": { "@type": "MedicalCode", "code": "D008722", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E05.581" } } }, "about": { "@type": "MedicalCondition", "name": "Groupes témoins", "alternateName": "Control Groups", "code": { "@type": "MedicalCode", "code": "D035061", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Thomas Steger-Hartmann", "url": "https://questionsmedicales.fr/author/Thomas%20Steger-Hartmann", "affiliation": { "@type": "Organization", "name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany." } }, { "@type": "Person", "name": "Tania Rivera-Hernandez", "url": "https://questionsmedicales.fr/author/Tania%20Rivera-Hernandez", "affiliation": { "@type": "Organization", "name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia." } }, { "@type": "Person", "name": "Mark J Walker", "url": "https://questionsmedicales.fr/author/Mark%20J%20Walker", "affiliation": { "@type": "Organization", "name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia." } }, { "@type": "Person", "name": "Mark R Davies", "url": "https://questionsmedicales.fr/author/Mark%20R%20Davies", "affiliation": { "@type": "Organization", "name": "Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia." } }, { "@type": "Person", "name": "Alexander Gurjanov", "url": "https://questionsmedicales.fr/author/Alexander%20Gurjanov", "affiliation": { "@type": "Organization", "name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany. Electronic address: alexander.gurjanov@bayer.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Attachment in adolescents with attention deficit hyperactivity disorder and oppositional defiant disorder.", "datePublished": "2022-06-30", "url": "https://questionsmedicales.fr/article/36342984", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.12740/PP/OnlineFirst/130366" } }, { "@type": "ScholarlyArticle", "name": "Prevalence of Personality Disorders in Adults With Attention Deficit Hyperactivity Disorder (ADHD).", "datePublished": "2023-03-16", "url": "https://questionsmedicales.fr/article/36927130", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/10870547231161531" } }, { "@type": "ScholarlyArticle", "name": "Pragmatic Deficits in Attention Deficit/Hyperactivity Disorder: Systematic Review and Meta-Analysis.", "datePublished": "2023-03-28", "url": "https://questionsmedicales.fr/article/36975307", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/10870547231161534" } }, { "@type": "ScholarlyArticle", "name": "Oculomotor deficits in attention deficit hyperactivity disorder: a systematic review and meta-analysis.", "datePublished": "2022-10-24", "url": "https://questionsmedicales.fr/article/36280758", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41433-022-02284-z" } }, { "@type": "ScholarlyArticle", "name": "Characterizing the metabolomic signature of attention-deficit hyperactivity disorder in twins.", "datePublished": "2023-04-25", "url": "https://questionsmedicales.fr/article/37100381", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.neuropharm.2023.109562" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Techniques d'investigation", "item": "https://questionsmedicales.fr/mesh/D008919" }, { "@type": "ListItem", "position": 3, "name": "Méthodes", "item": "https://questionsmedicales.fr/mesh/D008722" }, { "@type": "ListItem", "position": 4, "name": "Groupes témoins", "item": "https://questionsmedicales.fr/mesh/D035061" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Groupes témoins - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Groupes témoins", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Groupes témoins", "description": "Comment identifier un groupe témoin ?\nQuel est le rôle d'un groupe témoin ?\nComment choisir un groupe témoin ?\nLes groupes témoins sont-ils toujours nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Groupes témoins", "description": "Les groupes témoins montrent-ils des symptômes ?\nComment les symptômes sont-ils évalués ?", "url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Groupes témoins", "description": "Les groupes témoins aident-ils à la prévention ?\nComment les groupes témoins influencent-ils la prévention ?", "url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Groupes témoins", "description": "Quel type de traitement est comparé ?\nComment les résultats sont-ils mesurés ?", "url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Groupes témoins", "description": "Les complications sont-elles observées dans les groupes témoins ?\nComment les complications sont-elles analysées ?", "url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Groupes témoins", "description": "Les groupes témoins aident-ils à identifier des facteurs de risque ?\nComment les facteurs de risque sont-ils évalués ?", "url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier un groupe témoin ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un groupe témoin est constitué de participants similaires au groupe traité, mais sans intervention." } }, { "@type": "Question", "name": "Quel est le rôle d'un groupe témoin ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Il permet d'évaluer l'effet d'un traitement en comparant les résultats avec ceux du groupe traité." } }, { "@type": "Question", "name": "Comment choisir un groupe témoin ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Le choix doit se baser sur des critères d'inclusion similaires à ceux du groupe traité." } }, { "@type": "Question", "name": "Les groupes témoins sont-ils toujours nécessaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont essentiels pour établir des comparaisons valides dans les études cliniques." } }, { "@type": "Question", "name": "Les groupes témoins montrent-ils des symptômes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils ne reçoivent pas de traitement, donc ils ne présentent pas de symptômes liés au traitement." } }, { "@type": "Question", "name": "Comment les symptômes sont-ils évalués ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes sont évalués par des questionnaires ou des examens cliniques dans les deux groupes." } }, { "@type": "Question", "name": "Les groupes témoins aident-ils à la prévention ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils permettent d'évaluer l'efficacité des interventions préventives par comparaison." } }, { "@type": "Question", "name": "Comment les groupes témoins influencent-ils la prévention ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Ils fournissent des données sur l'impact des mesures préventives en comparaison avec l'absence d'intervention." } }, { "@type": "Question", "name": "Quel type de traitement est comparé ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement expérimental est comparé à un placebo ou à un traitement standard dans le groupe témoin." } }, { "@type": "Question", "name": "Comment les résultats sont-ils mesurés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les résultats sont mesurés par des critères prédéfinis, comme l'amélioration des symptômes." } }, { "@type": "Question", "name": "Les complications sont-elles observées dans les groupes témoins ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent être observées, mais elles ne sont pas dues au traitement expérimental." } }, { "@type": "Question", "name": "Comment les complications sont-elles analysées ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont analysées en comparant leur fréquence entre le groupe témoin et le groupe traité." } }, { "@type": "Question", "name": "Les groupes témoins aident-ils à identifier des facteurs de risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils permettent de comparer les facteurs de risque entre les groupes traité et témoin." } }, { "@type": "Question", "name": "Comment les facteurs de risque sont-ils évalués ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont évalués par des questionnaires et des analyses statistiques dans les deux groupes." } } ] } ] }

Sources (10000 au total)

Attachment in adolescents with attention deficit hyperactivity disorder and oppositional defiant disorder.

To assess attachment styles among adolescents (13-16 years) with ADHD or ADHD and oppositional defiant disorders (ODD).... The Parents and Peers Attachment (IPPA) and the Parent Bonding Questionnaire (PBI) were used in three groups of teenagers raised in biological families: (1) ADHD/ODD group (n = 40), (2) ADHD group (n ... Parental attachment styles in the area of "Trust", "Communication" and "Alienation" (IPPA), and "Care" and "Control" (PBI) in the ADHD/ODD group differ significantly compared to the control group. Tee... The attachment style is significantly different in adolescents diagnosed with ADHD and ODD than in adolescents with only ADHD. In the ADHD/ODD group and the ADHD group, unlike in the group of adolesce...

Prevalence of Personality Disorders in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

To estimate the prevalence of PDs according to Millon's evolution-based model among adult ADHD outpatients.... Cross-sectional study of consecutive patients referred to an adult ADHD clinic. PDs were evaluated with Millon Clinical Multiaxial Inventory-III (MCMI-III).... One-hundred-eighty-one participants had valid MCMI-III, of whom147 were diagnosed with ADHD. Mean age: 32.97, SD:11.56, females: 74 (50.3%). Among the 147 participants with ADHD, 29 (19.7%) did not me... Particular personality profiles were more common with different ADHD subtypes. Given the developmental origins of PD, further research may help identify possible links with childhood difficulties....

Pragmatic Deficits in Attention Deficit/Hyperactivity Disorder: Systematic Review and Meta-Analysis.

While poorer pragmatic language skills have been found in attention-deficit/hyperactivity disorder (ADHD) populations, there has been no conclusive evidence of this. We aimed to conduct a meta-analysi... Studies were identified using the search terms ((attention deficit) OR (adhd)) AND (pragmatics), and those studies were screened and reviewed for inclusion criteria, descriptive information, and outco... A total of 14 studies (5,772 participants) met the criteria for quantitative synthesis. Meta-analysis indicated that ADHD populations exhibited significantly poorer pragmatic language skills than TD p... It is suggested that pragmatic language skills may deserve greater surveillance considering the importance of pragmatic language in socio-emotional development, daily life, and academic success....

Attention deficit and hyperactivity disorder disrupts selective mechanisms of action.

People with attention deficit and hyperactivity disorder (ADHD) present attentional and emotional deficits and show paradoxical qualities such as hyperfocus. Previous studies have reported errors, slo... Thirty French children and teenagers, 15 with ADHD and 15 neurotypical (NT), underwent a saccadic eye movement task. We conducted conventional analysis (movement duration, precision, velocity, RT) and... Saccade duration and velocity failed to differentiate the two groups, whereas amplitude was higher in ADHD than in NT participants. Saccade RT and variability were higher in ADHD than in NT participan... ADHD disrupts two mechanisms of action: it reduces the gain of the decision signal, thus explaining slowness and variability; it quickens the decision process of early responses at the origin of short... These premises and their interconnections explain previous observations and support the striatal-frontal wiring of ADHD, thus explaining ADHD complexity in its negative and positive manifestations....

Psychiatric Comorbidities and Schizophrenia in Youths With Attention-Deficit/Hyperactivity Disorder.

The association between attention-deficit/hyperactivity disorder (ADHD) and schizophrenia has received increased attention; however, evidence on the association between psychiatric comorbidities and s... To investigate the risk of being diagnosed with schizophrenia in children and adolescents with ADHD considering the presence of psychiatric comorbidity.... This was a population-based, retrospective cohort study using the Health Insurance Review and Assessment claims database from January 1, 2007, to December 31, 2019. Participants were children and adol... The presence of psychiatric comorbidity was assessed from diagnosis records within 1 year before ADHD diagnosis. Comorbidities were further categorized according to the number of comorbidities and spe... Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs, examining the association between psychiatric comorbidities and the risk of being diagnosed with schizophrenia. Fu... A total of 211 705 patients with newly diagnosed ADHD were included. A total of 157 272 patients (74.3%) were male, and the age of 5 to 9 years showed the highest distribution (115 081 patients [54.4%... In this retrospective cohort study involving children and adolescents with ADHD, the presence of psychiatric comorbidity in patients with ADHD was associated with an increased risk of being diagnosed ...